98453-58-8

Upstream product

• 32281-97-3 7-bromo-3,4-dihydro-2H-naphthalen-1-one 
• 544-97-8 dimethyl zinc(II) 
• 98453-57-7 4-(4-bromophenyl)butanoic acid methyl ester 
• 6340-79-0 4-oxo-4-(4-bromophenyl)butanoic acid 
• 35656-89-4 4-(4-bromophenyl)butanoic acid 
• 108-86-1 bromobenzene 
• 67962-10-1 1-(4'-bromophenyl)-4-methyl-1-penten-3-one 
• 1122-91-4 4-bromo-benzaldehyde 
• 563-80-4 3-methyl-butan-2-one 
• 87077-85-8 2-methyl-5-(4-bromophenyl)-2-pentanol 

Downstream Products

• 205385-99-5 (S)-2-{[3-(2-tert-Butoxycarbonylamino-3-hydroxy-propyl)-5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl]-methyl-amino}-3-methyl-butyric acid benzyl ester 
• 98453-67-9 C₁₉H₁₉BrN₂O₂S 
• 98453-60-2 6-bromo-3,4-dihydro-4,4-dimethylnaphthalen-1(2H)-one 

Relevant academic research and scientific papers

aromatic compound having fused cyclic substituent in aromatic ring and organic light-emitting diode including the same

The present invention relates to a compound having a cyclic substituent fused with a cyclic ring and an organic light emitting diode including the same, and more particularly, to a compound for an organic light emitting diode represented by chemical formula A and an organic light emitting diode including the same. In chemical formula A, X is a substituent having structural formula X, Y is a substituent of structural formula Y1, n is an integer from 1 to 4, and structural formulas X and Y1 are the same as described in detailed description of the present invention.

aromatic compound having fused cyclic substituent in aromatic ring and organic light-emitting diode including the same

The present invention refers to to the aromatic ring-fused ring withdrawing substituent and a compound having an same relates to organic light emitting device including, more specifically a represented by [formula A] an alkali-soluble polymer resin compound for an organic light-emitting device including organic light emitting device is characterized in that the. [Formula A] In said [formula A], X has a dementia drug; and shows strong X having substituted group, Y has a dementia drug; and shows strong formula selected from the group consisting Y1 to Y5 having one of substituted group, the n being integers, of 4 to 1, the Y5 formula to Y1 formula and X formula detailed description of the invention is described. (by machine translation)

Retinoid receptor subtype-selective modulators through synthetic modifications of RARγ agonists

A series of retinoids designed to interfere with the repositioning of H12 have been synthesized to identify novel RARγ antagonists based on the structure of known RARγ agonists. The transcriptional activities of the novel ligands were revealed by cell-based reporting assays, using engineered cells containg RAR subtype-selective fusions of the RAR ligand-binding domains with the yeast GAL4 activator DNA-binding domain and the cognate luciferase reporter gene. Whereas none of the ligands exhibited features of a selective RARγ antagonist, some of them are endowed with interesting activities. In particular 24a acts as a pan-RAR agonist that induces at high concentration a higher transactivation potential on RARα than TTNPB and synergizes at low concentration with TTNPB-bound RARα but not RARβ or RARγ. Similarly, 24c synergizes with TTNPB-bound RARγ and exhibits RARα,β antagonist activity. Compounds 24b and 25b are strong RARα,β-selective antagonists without agonist or antagonist activities for RARγ. Compounds 24b and 24c display weak RXR antagonist activity. In addition several pan-antagonists and partial agonist/antagonists have been defined.

DISUBSTITUTED CHALCONE OXIMES HAVING RARγ RETINOID RECEPTOR ANTAGONIST ACTIVITY

Compounds of the formula where the variables have the values described in the specification are antagonists of RARγ retinoid receptors.

Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors

Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RARγ agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.

5-[PHENYL-TETRAHYDRONAPHTHALENE-2-YL DIHYDRONAPHTHALEN-2-YL AND HETEROARYL-CYCLOPROPYL]-PENTADIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY

Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of reducing serum thyroxine levels and transiently increasing triglyceride levels.

NOVEL LIGANDS THAT ARE ANTAGONISTS OF RAF RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS

The invention relates to novel compounds corresponding to formula (I) below: and to the method for preparing them, and to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or alternatively in cosmetic compositions.

Clarification of the binding mode of teleocidin and benzolactams to the Cys2 domain of protein kinase Cδ by synthesis of hydrophobically modified, teleocidin-mimicking benzolactams and computational docking simulation

Phorbol esters (12-O-tetradecanoylphorbol 13-acetate; TPA) and teleocidins are known to be potent tumor promoters and to activate protein kinase C (PKC) by binding competitively to the enzyme. The relationship between the chemical structures and the activities of these compounds has attracted much attention because of the marked structural dissimilarities. The benzolactam 5, with an eight-membered lactam ring and benzene ring instead of the nine-membered lactam ring and indole ring of teleocidins, reproduces the active ring conformation and biological activities of teleocidins. Herein we describe the synthesis of benzolactams with hydrophobic substituents at various positions. Structure-activity data indicate that the existence of a hydrophobic region between C-2 and C-9 and the steric factor at C-8 play critical roles in the appearance of biological activities. We also computationally simulated the docking of teleocidin and the modified benzolactam molecules to the Cys2 domain structure observed in the crystalline complex of PKCδ with phorbol 13-acetate. Teleocidin and benzolactams fitted well into the same cavity as phorbol 13-acetate. Of the three functional groups hydrogenbonding to the protein, two hydrogen-bonded with protein atoms in common with phorbol 13-acetate, but the third one hydrogen-bonded with a different protein atom from that in the case of phorbol 13-acetate. The model explains well the remarkable difference in activity between 5 and its analogue having a bulky substituent at C-8.

SUBSTITUENT EFFECTS ON THE RATE OF CARBENE FORMATION BY THE PYROLYSIS OF RIGID ARYL SUBSTITUTED DIAZOMETHANES

Rate constants for the pyrolysis of 1-diazo-4,4-dimethyl-1,4-dihydronaphtalenes, 4a-4e, have been measured in methanol:6percent triethylamine.In contrast to non-rigid cases, like diphenyldiazomethanes, where all para substituents show a rate increase compared to hydrogen, these rates show a linear Hammett correlation for all para substituents with ?+ = -0.84.This observation is rationalized by a non-linear process for loss of nitrogen leading directly to the ground-state singlet of the carbene, 17.This carbene is then trapped to give ether 11.